{
    "id": 25924,
    "fullName": "FGF19 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "FGF19 over exp indicates an over expression of the Fgf19 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 9965,
        "geneSymbol": "FGF19",
        "terms": [
            "FGF19"
        ]
    },
    "variant": "over exp",
    "createDate": "01/17/2017",
    "updateDate": "01/17/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19587,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with hepatocellular carcinoma overexpressing FGF19 was sensitive to treatment with Fisogatinib (BLU-554), demonstrating a partial response with a 44% decrease in tumor size after 16 weeks (PMID: 31575540).",
            "molecularProfile": {
                "id": 27058,
                "profileName": "FGF19 over exp"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12733,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF19 overexpression was associated with sensitivity to H3B-6527 in hepatocellular carcinoma cell lines in culture and in xenograft models, and in hepatocellular carcinoma patient-derived xenograft (PDX) models (PMID: 29247039).",
            "molecularProfile": {
                "id": 27058,
                "profileName": "FGF19 over exp"
            },
            "therapy": {
                "id": 6610,
                "therapyName": "H3B-6527",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10667,
                    "pubMedId": 29247039,
                    "title": "H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247039"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10806,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU9931 inhibited Fgfr4 function and proliferation in patient-derived hepatocellular carcinoma cell lines with elevated Fgf19 expression, and demonstrated anti-tumor effects in patient-derived xenograft models (PMID: 25776529).",
            "molecularProfile": {
                "id": 27058,
                "profileName": "FGF19 over exp"
            },
            "therapy": {
                "id": 2509,
                "therapyName": "BLU9931",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2415,
                    "pubMedId": 25776529,
                    "title": "First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25776529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9769,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hepatocellular carcinoma cell line over expressing FGF19 demonstrated sensitivity to ASP5878, resulting in inhibition of cell proliferation in culture and tumor regression in cell line xenograft models (PMID: 27837028).",
            "molecularProfile": {
                "id": 27058,
                "profileName": "FGF19 over exp"
            },
            "therapy": {
                "id": 3584,
                "therapyName": "ASP5878",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7585,
                    "pubMedId": 27837028,
                    "title": "ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27837028"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12736,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of H3B-6527 and Ibrance (palbociclib) resulted in tumor regression and enhanced tumor growth inhibition compared to H3B-6527 alone in cell line xenograft models of hepatocellular carcinoma with overexpression of FGF19 (PMID: 29247039).",
            "molecularProfile": {
                "id": 27058,
                "profileName": "FGF19 over exp"
            },
            "therapy": {
                "id": 6611,
                "therapyName": "H3B-6527 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10667,
                    "pubMedId": 29247039,
                    "title": "H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247039"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19464,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF401 did not inhibit tumor growth in a FGFR4-positive, KLB-negative, and FGF19 amplified and overexpressing patient-derived xenograft (PDX) model of gastric cancer (PMID: 31409633).",
            "molecularProfile": {
                "id": 34161,
                "profileName": "FGF19 amp FGF19 over exp FGFR4 pos KLB neg"
            },
            "therapy": {
                "id": 2031,
                "therapyName": "FGF401",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19588,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with hepatocellular carcinoma overexpressing FGF19 initially responded to Fisogatinib (BLU-554) treatment, but progressed at week 32 and was found via circulating tumor DNA testing to have acquired FGFR4 V550M, FGFR4 V550L, and FGFR4 C552R (PMID: 31575540).",
            "molecularProfile": {
                "id": 34258,
                "profileName": "FGF19 over exp FGFR4 V550L FGFR4 V550M FGFR4 C552R"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19589,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with hepatocellular carcinoma and overexpression of FGF19 initially experienced stable disease and a 15% decrease in tumor size when treated with Fisogatinib (BLU-554), but then progressed and was found via circulating tumor DNA to have acquired FGFR4 V550M (PMID: 31575540).",
            "molecularProfile": {
                "id": 34266,
                "profileName": "FGF19 over exp FGFR4 V550M"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27058,
            "profileName": "FGF19 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34161,
            "profileName": "FGF19 amp FGF19 over exp FGFR4 pos KLB neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34258,
            "profileName": "FGF19 over exp FGFR4 V550L FGFR4 V550M FGFR4 C552R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34266,
            "profileName": "FGF19 over exp FGFR4 V550M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}